Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
NCT00044057 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or placebo, is administered prior to the completion of the t-PA administration. The clinical effects of YM872 in addition to t-PA will be determined by assessing neurological function and disability scores at follow up visits through Day 90 of the study.
Conditions Studied
Interventions
- DRUG YM872 (zonampanel), t-PA (alteplase)
Study Locations (20)
California
- East Bay Region Associates in Neurology — Berkeley
- Providence St. Joseph's Medical Center — Burbank
- Mercy San Juan Hospital — Carmichael
- University of California Davis Medical Center — Davis
- Scripps Memorial Hospital — Encinitas
- Grossmont Hospital — La Mesa
- UCLA Medical Center — Los Angeles
- Tri-City Medical Center — Oceanside
- Stanford University Medical Center — Palo Alto
- Mercy General Hospital — Sacramento
- Scripps Mercy Hospital — San Diego
- University of California at San Diego — San Diego
- Good Samaritan Hospital — San Jose
- UCLA Medical Center - Santa Monica — Santa Monica
- John Muir Medical Center — Walnut Creek
- Mt Diablo Medical Center — Walnut Creek
Arizona
- Good Samaritan Hospital — Phoenix
- University of Arizona — Tucson
Alabama
- University of South Alabama Stroke Center — Mobile
Colorado
- Colorado Neurological Institute — Englewood
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044057
The ClinicalTrials.gov registry entry for NCT00044057 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Astellas Pharma, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention — of which YM872 (zonampanel), t-PA (alteplase) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00044057 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Arizona, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00044057 about?
NCT00044057 is a clinical study titled "A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)". The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or placebo, is administered prior to...
What is the current status of trial NCT00044057?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-12. Estimated completion is 2003-01.
What conditions does trial NCT00044057 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00044057?
The interventions under investigation include: YM872 (zonampanel), t-PA (alteplase) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00044057?
This trial is sponsored by Astellas Pharma, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00044057 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.